The effect of human wharton’s jelly-derived mesenchymal stem cells on MC4R, NPY, and LEPR gene expression levels in rats with streptozotocin-induced diabetes

Fatemeh Sabet Sarvestani 1, Mohammad Ali Zare 1, Forough Saki 2, Farhad Koohepyma 2, Ismail H Al-Abdullah 3, Negar Azarpira *

1Transplant Research Center, Shiraz University of Medical Sciences, Shiraz, Iran
2Endocrinology and Metabolism Research Center, Shiraz University of Medical Sciences, Shiraz, Iran
3Department of Translational Research and Cellular Therapeutics, Diabetes and Metabolism Research Institute, Beckman Research Institute of City of Hope, Duarte, USA

ARTICLE INFO
Article type: Original article
Article history: Received: Apr 13, 2019 Accepted: Aug 3, 2019

Keywords: Diabetes mellitus Leptin Neuropeptide Y Receptor Stem cells Wharton jelly

ABSTRACT
Objective(s): Type 1 diabetes (T1D) is an autoimmune disease resulting from inflammatory destruction of islets β-cells. Nowadays, progress in cell therapy, especially mesenchymal stem cells (MSCs) proposes numerous potential remedies for T1D. We aimed to investigate the combination therapeutic effect of these cells with insulin and metformin on neuropeptide Y, melanocortin-4 receptor, and leptin receptor genes expression in T1D.

Materials and Methods: One hundreds male rats were randomly divided into seven groups: the control, diabetes, insulin (Ins.), insulin+metformin (Ins.Met.), Wharton’s Jelly-derived MSCs (WJ-MSCs), insulin+metformin+WJ-MSCs (Ins.Met.MSCs), and insulin+WJ-MSCs (Ins.MSCs). Treatment was performed from the first day after diagnosis as diabetes. Groups of the recipient WJ-MSCs were intraportally injected with 2× 10⁶ MSCs/kg at the 7th and 28th days of study. Fasting blood sugar was monitored and tissues and genes analysis were performed.

Results: The blood glucose levels were slightly decreased in all treatment groups within 20th and 45th days compared to the diabetic group. The C-peptide level enhanced in these groups compared to the diabetic group, but this increment in Ins.MSCs group on the 45th days was higher than other groups. The expression level of melanocortin-4 receptor and leptin receptor genes meaningfully up-regulated in the treatment groups, while the expression of neuropeptide Y significantly down-regulated in the treatment group on both times of study.

Conclusion: Our data exhibit that infusion of MSCs and its combination therapy with insulin might ameliorate diabetes signs by changing the amount of leptin and subsequent changes in the expression of neuropeptide Y and melanocortin-4 receptor.

Introduction
Type 1 diabetes mellitus (T1DM) is an immune-mediated disorder that results from autoimmune destruction of pancreatic islet β-cells, which leads to little or no insulin production and uncontrolled high blood glucose levels. At the time of clinical diagnosis, 60-80% of pancreatic β-cells have been destroyed. Thus, regeneration of the endocrine pancreatic tissue is one of the strategies to treat T1DM (1).

Recently, stem cell therapy has achieved positive results in medicine related to the 3Rs (Replacement, Repair, and Regeneration). In fact, stem cell therapy has been applied successfully in diabetes, from preclinical to clinical studies (2-14). Mesenchymal stem cells (MSCs) are multipotent stromal cells with the capability of self-renewal and differentiation into a variety of cells (15). These cells have great potential, and it is feasible to isolate them; in addition, there is an abundant source, and ethical concerns are minimal. MSCs are isolated from various tissues, including adipose tissue, bone marrow, umbilical cord blood, umbilical cord, and dental pulp (16-18). When these cells are cultured in vitro, they appear as spindle-shaped cells. Furthermore, these cells express a specific marker profile; they are positive for CD29, CD51, CD73, CD90, and CD105 expression, while negative for hematopoietic markers such as CD31 and CD45 (19). Recently, MSCs have been considered as therapies for a wide range of diseases due to modulating immune responses and regenerative properties (20). Actually, human umbilical cord MSCs (hUC-MSCs) are adult stem cells, which are capable to differentiate into several cell phenotypes in vitro and in vivo (21). Interestingly, they do not express major histocompatibility complex (MHC) class II and only express MHC class I at low levels. Moreover, they do not express Fas ligand and co-stimulatory molecules such as B7 and CD40, thus they have been suggested to be hypoimmunogenic cells (22). Other properties include their ability to self-renew, to create colony forming units, and to differentiate into other cells such as bone, cartilage, and fat. The aforementioned characteristics are part of the criteria used to determine and identify...
MSCs (23). Moreover, MSCs can differentiate into myocytes, neuronal cells, and potentially, β-pancreatic islets cells. In some studies, it has been shown that MSCs have potential of differentiation into insulin-producing and islet-like cells (24-27). In addition to their differentiation potential, MSCs have been reported to regulate the immune response in many diseases (28-30). Maldonado et al. showed that human umbilical cord Wharton jelly cells (hUCWJCs) can migrate to damaged tissues and promote insulin secretion from non-pancreatic local cells (31). The differentiation potential and immunomodulatory feature of MSCs make these cells ideal candidates for the preservation of islet β cell function in patients with T1D (32).

Energy homeostasis is regulated by the interaction of nutrients and hormones with subpopulations of neurons located in several distinct areas of the brain. The hypothalamus, predominantly the arcuate nucleus (ARC), plays an important role in regulating food intake, energy expenditure and glucose metabolism. There are many factors to consider in the hypothalamic regulation of food intake, such as melanin-concentrating (MCH), Neuropeptide Y (NPY), agouti-related protein (AgRP), and proopiomelanocortin (POMC) (33).

Leptin (LEP) is a hormone, primarily derived from adipose tissue, with anti-diabetic features that regulates numerous physiological processes and behaviors, including appetite, body weight, neuroendocrine functions, and hypoglycemia. These actions are mediated through leptin receptors (LEPR) activated by the nervous system (34). The POMC neurons in the ARC are activated by LEP. In fact, LEP is secreted by adipocytes, enters the CNS, and acts on its receptor expressed in key brain areas that regulate metabolism. This hormone inhibits NPY/AgRP neurons and stimulates POMC neurons in the ARC, responses to stimulation of glucose uptake in peripheral tissues and the suppression of glucose production from the liver. In addition, LEP induces gluconeogenesis via a melanocortin-dependent pathway (35-37) (Figure 1). Also, intracerebroventricular (ICV) infusing of LEP improved hyperglycemia, hyperglucagonemia, hyperketonemia, and polyuria caused by insulin deficiency in mice. Furthermore, ICV LEP delivery improves expression of the metabolically relevant hypothalamic neuropeptides POMC, NPY, and AgRP in T1D mice (38).

The aim of this study was to investigate the combination and segregation effects of WJ-MSCs, insulin, and metformin on blood glucose, C-peptide level, and expression of genes associated with metabolisms in T1D rat model.

**Materials and Methods**

**Animals, experimental groups, and diabetes induction**

One hundred adult male Sprague-Dawley rats (3-4 months old), weighing 200±20 g were used in the present randomized controlled experimental study. The rats were housed in the Center of Comparative and Experimental Medicine of Shiraz University of Medical Sciences, Shiraz, Iran, under controlled temperature (22 °C) and lighting (12 hr: 12 hr light to dark ratio; light on at 7:30 AM) conditions. All experimental procedures on the rats were carried out between 7.00- 9.00 AM and based on the recommendations of the Animal Care Committee of the Shiraz University of Medical Sciences (SUMs) (Ethical code: IR.SUMS.REC.1395.S673). In this experiment, a single dose (60 mg/kg) of Streptozotocin (STZ) (Sigma) was administered via the intraperitoneal (IP) cavity to develop T1D model (39, 40). Three weeks after STZ injection, fasting plasma glucose (FPG) of all rats were tested, and rat with blood glucose higher than 200 mg/dl was considered as diabetic. A few animals died during this period and were excluded from the study. Other animals were randomly divided into 7 groups: the control (n=10), diabetes (n=10), insulin (Ins.) (n=10), insulin+metformin (Ins.Met.) (n=10), MSC (n=10), Ins.Met.MSCs (n=10), and Ins.MSCs (n=10). Rats were treated everyday with insulin and metformin according to previously published protocols (41, 42) and received WJ-MSCs intraperitoneally twice with 2×10⁶ MSCs/kg at the first week and fourth weeks of study after diabetes confirmation according to the groups mentioned above (32). Daily fasting blood sugars were monitored in the treatment groups during the experiment. Finally, all rats were sacrificed to acquire blood and brain tissues for analysis on the 20th and 45th days of study.

**Isolation, Culture and Characterization of WJ-MSC**

Human umbilical cords (n=4) were collected from obstetric department affiliated to Shiraz University of Medical Sciences (SUMs), Shiraz, Iran. Informed consent was obtained from mothers, and the study was approved by our ethical committee of SUMS. Infectious pathology was excluded by the performance of human immunodeficiency virus (HIV), hepatitis C virus (HCV), and hepatitis B virus (HBV) tests. The tissues were stored in Hank’s balanced salt solution (HBSS; BiochromL201-10) containing antibiotics (penicillin 100 U/ml, streptomycin 100 μg/ml) on the ice. The
isolation of MSCs was performed according to previously reported methods (43-45). Briefly, umbilical cord was disinfected by rinsing with 70% ethanol for 30 sec, and was then dissected with scissors into pieces around 1-3 mm³ in volume. These tissue pieces were plated in a cell culture dish under standard conditions using DMEM (Dulbecco's Modified Eagle Medium) containing 10% fetal bovine serum (FBS) supplemented with 100 U/ml penicillin, and 100 µg/ml streptomycin (GIBCO, USA). Cell cultures were maintained in a humidified atmosphere with 5% CO₂ at 37 °C.

**Immunochemistry**
To phenotype cell-surface antigens, fourth-passage cells were stained by conjugated antibodies specific for the following human antigens: CD90-FITC, CD44-FITC, and CD34- FITC, (BioLegend, USA) and compared to corresponding isotype control. Stained cells were analyzed using FACSCalibur flowcytometer (Becton Dickinson, USA). For each sample, at least 10,000 events were recorded (23).

**Biochemical analysis**
The rats were anesthetized with an IP injection of ketamine (100 mg/kg) and xylazine (10 mg/kg). Then, blood samples were collected from all rats by heart puncture at the time of death. Blood samples were centrifuged at 3500 rpm at 25 °C for 10 min, and serum was stored at −80 °C for further assays. Serum levels of C-peptide were measured with enzyme-linked immunosorbent assay (ELISA) kit (RayBiotech, Norcross, Georgia). All samples were measured in duplicate. In addition, fasting blood glucose (FBG) in treatment groups were monitored daily by glucometer (ACCU-Chek Performa, USA).

**Tissue harvesting**
**Brain**
In order to harvest brain tissue, the rats were decapitated and brains were removed immediately. The diencephalon was dissected out by an anterior coronal section, anterior to the optic chiasm, and a posterior coronal cut at the posterior border of the mamillary bodies. To separate ARC from anteroverentral periventricular nucleus (AVPV), a third coronal cut was made through the middle of the optic tract, just rostral to the infundibulum (46). The specimens consisting of ARC and dorsomedial hypothalamic nucleus (DMH) were stored in liquid nitrogen for molecular study.

**Pancreas**
Pancreas tissues were harvested in control and diabetic rats for histology and in some treated groups on the 45th day for immunohistochemistry (IHC) staining. The tissues were fixed overnight in a solution of freshly prepared 4% paraformaldehyde in 0.1 M PBS, pH 7.4, at 4 °C. Samples were dehydrated and prepared as paraffin blocks, serially cut into 5 µm sections at 50 µm intervals, stained with hematoxylin and eosin (H&E) and examined by light microscopy.

**Immunohistochemistry**
To detect insulin in pancreatic sections, primary anti-insulin antibody (1:100; DAKO, USA) were used. The appropriate primary antibody was added in blocking buffer and incubated overnight at 4 °C. Sections were washed and incubated with secondary antibody for 30 min at room temperature, followed by washing and incubation with diaminobenzidine (DAB) as chromogen (Master Polymer Plus Detection System (Peroxidase), Granada, Spain) for 5 min. Sections were counterstained with hematoxylin for 2 to 5 min and mounted [43].

**RNA isolation and real time PCR**
Total RNA from 50-100 mg of brain tissue was isolated using TRIzol Reagent (Life Technologies, Rockville, Md, USA) according to the manufacturer’s instructions. The quantity of the extracted RNA was evaluated by Nanodrop (measuring the optical density 260/280), and the quality of RNA was assessed by running 3 µl on 1% agarose gel. The good quality was indicated by the lack of a smear and presence of 28S and 18S ribosomal RNA (rRNA). The total RNA was reverse-transcribed into cDNA using Prime Script RT Reagent Kit (Takara, Japan) according to the manufacturer’s guidelines.

Primers were designed using Allele ID 7 and Oligo 7 software (Premier Biosoft International, Palo Alto, USA) for LEPR (NM_012596.1), melanocortin 4 receptor (MC4R) (NM_013099.3), NPY (NM_012614.2), and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) (NM_017008.4). The rat GAPDH gene was used as the reference gene for data normalization (Table 1).

| Primer     | Sequence                                      | Amplicon length (bp) |
|------------|-----------------------------------------------|----------------------|
| MC4R-F     | 5′-ACGGGTCAGAAACCAGATGTC-3′                  | 115                  |
| MC4R-R     | 5′-GCCAGGAAAGGAGCTACAGAT-3′                  | 131                  |
| LEPR-F     | 5′-GCCATCAATCATGCTGGGC-3′                    | 150                  |
| LEPR-R     | 5′-GTCCAGGAAAGGATGAGGGA-3′                   | 100                  |
| NPY-F      | 5′-CTGGGACACTACATCAAT-3′                     |                      |
| NPY-R      | 5′-CATTTCCATGACGACAT-3′                      |                      |
| GAPDH-F    | 5′-AAAGAGATGCTGAGAGGGC-3′                    |                      |
| GAPDH-R    | 5′-ACAGGGAAAGACTGTTCCGAGA-3′                 |                      |

MC4R: Melanocortin-4 receptor; NPY: Neuropeptide Y; LEPR: Leptin receptor; GAPDH; Glyceraldehyde-3-phosphate dehydrogenase
The expression levels of MC4R, NPY, and LEPR were determined by Livak \(2^{-\Delta\Delta CT}\) method. Melt curves were also analyzed to confirm the specificity of reaction at the end of the program.

**Statistical analysis**

All statistical analyses were performed using SPSS version 19.0 software (SPSS Inc., Chicago, USA). The results were expressed as mean±SD values, and statistical significance was determined by one-way ANOVA with Tukey's multiple comparison post hoc tests with \(P\)-value<0.05.

**Results**

**Characterization of WJ-MSCs**

The plastic-adherent cells from Wharton's jelly formed a monolayer with fibroblast-like morphology (Figure 2A). The flow cytometry results demonstrated that the WJ-MSCs expressed stromal markers (CD90, CD44), while were negative for the hematopoietic marker (CD34) (Figure 2B). After differentiation toward adipogenic and osteogenic lineage, the presence of lipid vacuoles was confirmed by Oil Red O; and calcium deposition revealed with Alizarin Red (Figure 2C).

**Animal general condition**

The high blood glucose levels (FBG > 200 mg/dl) confirmed diabetic rats (three weeks after STZ injection). After 45 days of therapy, polydipsia, polyphagia, urorrhagia, and loss of body weight were ameliorated in the treatment groups compared to the diabetic group. The weight of rats on the 20th and 45th days after therapy were significantly decreased in the diabetics groups compared to other groups, while the weight of rats on the 20th days in the treatment groups were decreased, but after this time were gradually elevated until the end of the study (Figure 3).

**Fasting blood glucose levels**

During the last period of study, the blood glucose levels in the diabetic group increased. Also, the blood glucose levels were more slightly decreased in the treatment groups than the diabetic group, but the change was not significant. The level of FBG in Ins. group has more reduction than other groups. Ins.MSCs, Ins.Met, and MSCs therapy groups exhibited similar decreasing

![Figure 2. Characterization of human wharton's jelly-derived mesenchymal stem cells. (A) The morphology of mesenchymal stem cells (MSCs). (B) The result of flowcytometry showed that cells were negative for CD34 (0.3%) and positive for CD44 (89.1%) and CD90 (95.4%). (C) Differentiation of MSC into adipocytes and osteocytes that confirmed by oil red O and alizarin red, respectively](image)

![Figure 3. Body weight. There was no significant difference between columns, which have at least one similar letter. However, this dissimilar letters indicated a significant difference (\(P<0.05\))](image)
trends and were almost close to the Ins. group. Although in Ins.Met.MSCs group the trend was observed, but overall the experiments showed a higher blood glucose level during the study (Figure 4).

C-peptide levels
Fasting C-peptide in all groups was examined and analyzed. There was no observed significant difference on the 20th days in the therapy groups in comparison with the diabetic group, while on the 45th day a significant increase in fasting C-peptide levels was observed in the Ins.MSCs, Ins., and MSCs groups (P-value<0.05) (Figure 5).

Histology and immunohistology
A marked destruction in pancreatic islets was confirmed in STZ-treated animals (Figure 6A). The presence of insulin-producing β cells in treatment groups were evaluated by IHC. The Ins.MSCs group revealed the better results; the islet size was larger with more insulin-positive cells. In comparison, the MSCs group showed fewer islet clusters with less insulin-positive cells, and the Ins.Met.MSCs group had only few scattered insulin-positive cells between exocrine tissue.

No insulin immunostaining cell was identified in the Ins. Met. group (Figure 6B).

Expression of MC4R, NPY, and LEPR genes in brain tissues
The expression of LEPR gene in ARC on days 20 and 45 was significantly increased in the Ins., Ins.Met. MSCs, and MSC groups compared to the diabetic group, but there was no significant difference in the Ins.Met. group than the diabetic group (Figure 7A). On the other hand, on day 20, LEPR gene expression was significantly increased in the Ins. group compared to the Ins.Met. and Ins.MSCs groups (P-value<0.05). The results in Figure 7B showed that MC4R gene expression on the 20th and 45th days was significantly increased in the Ins. Met and Ins.MSCs groups (P-value<0.05). As well, on the 45th days a significant increase in the gene expression was observed in the Ins.Met.MSCs group in comparison with the diabetic group.

The expression of NPY gene on the 20th days was significantly decreased among the treatment groups than to the diabetic group, but there were no
Figure 7. Expression of genes that control appetite and energy expenditure. (A, B) The expression level of LEPR and MC4R genes significantly up-regulated in the treatment groups ($P$-value<0.05). (C) The expression level of NPY gene significantly down-regulated in treatment group compared to diabetic group on the both time of study ($P$-value<0.05). a, b, c, and d: According to post hoc Tukey test that was used to make intergroup comparisons, groups with same superscripts were not significantly different at $\alpha$=0.05 ($P$-value≥0.05). However, dissimilar letters indicate a significant difference ($P$-value<0.05). (LEPR; Leptin receptor, MC4R; Melanocortin-4 receptor, NPY; Neuropeptide Y)

Discussion

T1D is a disease characterized by loss of insulin-producing $\beta$-cells as a result of an autoimmune-mediated destruction of Langerhans islet cells that leads to increased glucose and reduced C-peptide levels (45, 47). A usual therapy of T1D is whole organ or islet cells transplantation that has many limitations including lack of donors, rejections after transplantation, and requirement of long-term immune suppression (48). Recently, stem cells therapy has held immense promise for the treatment of patients with diabetes mellitus, from preclinical to clinical studies. Human MSC transplantations help to reduce blood glucose levels in diabetic animals and can improve blood glucose homeostasis in both type 1 and type 2 diabetic animals (49-51). In one study, a small proportion (6%) of diabetic MSCs expressed proinsulin and C-peptide, and these cells could differentiate rapidly into functional islet-like cells in the presence of a pseudo diabetic milieu (52). It has been suggested that the diabetic microenvironment may be a condition for MSC differentiation into insulin-producing cells in vitro and in vivo.

In other studies, labeled MSCs were transplanted into diabetic mice to determine their survival in body tissues. It was confirmed that the grafted cells presented and secreted functional human insulin and C-peptide (53, 54). A recent study by Maldonado et al. indicated that hUCWJCs after IP administration could migrate to damaged tissues and promote insulin secretion from non-pancreatic local cells (31). Similar previous studies in diabetic animal models have also shown that MSCs could alleviate blood glucose levels (53, 55, 56). Due to the absence of HMC class II and other co-stimulatory molecules on the surface of MSCs, they do not exhibit any immune response in the host tissue (15, 57).

In the present study, more insulin producing cells are present in the Ins.MSCs group, and it seems that treatment by Ins.MSCs may be better than cell therapy alone. Also, in our study, after the 20th day of therapy, FBG level in treatment groups, especially in the Ins. and Ins.MSCs groups, was lower than the control group. Also, after 45 days, blood glucose levels in all treatment groups decreased compared to the control group. C-peptide is co-secreted with insulin on an equimolar basis from the pancreatic beta cell (58), it is believed that C-peptide concentration reflected changes in insulin secretion more accurately than insulin concentration alone (59). In our study, the level of C-peptide in the treatment groups increased compared to the diabetic group. This increase was also higher in the Ins.MSCs group than other groups, and there was significant difference between the Ins., Ins.MSCs and MSCs therapy groups compared to other treatment groups, which suggests the positive combination effect of MSCs and insulin on the improvement of diabetes status that is consistent with previous findings (53, 54).

Metformin, an oral biguanide class of antihyperglycemic agent, is by far the most widely used glucose-lowering drug for type 2 diabetes mellitus (T2DM) (60). Besides common application in T2DM, metformin has been proved beneficial in patients with T1DM, due to the improvement of insulin sensitivity (61).

In a study by Zhou et al., metformin was shown to have a degenerative effect on beta cells (62), which reduces insulin secretion and subsequently reduces the amount of C-peptide. In our study, the C-peptide level was lower in the groups that received metformin. It seems that the adverse effect of metformin has been confirmed in our study (Figure 5). This finding is compatible with IHC result in the present study.

Glucose is the prime cellular energy source to keep up life, and therefore, its availability must be meticulously monitored (63, 64). The central nervous system (CNS) plays a crucial role in the regulation of energy and glucose homeostasis. The hypothalamus is one of the important regions involved in the central control of feeding and energy expenditure. The hypothalamus is constituted by distinct nuclei morphologically and functionally, including ARC, paraventricular (PVN), lateral hypothalamic area (LHA), ventromedial nucleus (VMN), and the dorsomedial nucleus (DMN), which all contain specific glucose-sensing neuronal populations.
In particular, the ARC of the hypothalamus is pivotal for the regulation of feeding and metabolism. Moreover, the ARC integrates hormonal and nutritional metabolic signal through the CNS. The ARC areas consisted of two antagonistic neuronal populations: one of them is the orexigenic (appetite-stimulating) NPY and AgRP; and the other is the anorexigenic (appetite-suppressing) including POMC and cocaine- and amphetamine-regulated transcript (67, 68). The overall balance between orexigenic and anorexigenic forces defines the final metabolic outcome (64). Moreover, ICV administration of insulin elevates the expression levels of POMC, which has an anorexigenic action and reduces the expression levels of NPY/AgRP that has an orexigenic action (69).

Previous studies have explained that insulin activates both LEP biosynthesis and secretion from white adipose tissue; LEP is able to improve metabolism, glucose and lipid levels in humans with T1D (70, 71). LEP is a peptide hormone with potent anti-diabetic actions that is produced and secreted by adipose tissue and relates to nutritional status (72). This hormone has important effects in the regulation of glucose homeostasis, food intake, and energy balance. LEP can alleviate diabetes via inhibition of the hypothalamic-pituitary-adrenal axis (73). These functions are mediated by actions on LEPR that is expressed by multiple neuronal groups in the CNS. Binding of LEP to LEPR triggers the activation of several intercellular pathways, including the Janus kinase/signal transducer and activator of transcription (68), mitogen-activated protein kinase, phosphoinositide 3-kinase (PI3K) (74), and mammalian target of rapamycin pathways (67, 75). LEP released from adipose tissue, go into ARC and acts on its receptors on two LEPr-sensitive neuronal populations in ARC. One of them is POMC neurons, which expresses POMC that leads to the release of α-melanocyte stimulating hormone, a key intermediate of this pathway that acts on melanocortin receptors (MC3R/MC4R) and subsequently leads to reduced food intake, increased energy expenditure, ameliorating insulin sensitivity, and developing weight loss (76, 77). On the other hand, acute central delivery of MC4R agonists in mice causes a potent reduction in plasma insulin levels, which is not secondary to a lowering of blood glucose or food intake (78). Consistently, mice with genetic loss or overexpression of melanocortin signaling exhibit changes in circulating insulin, irrespective of body weight and feeding (78, 79). Another one is NPY/AgRP neurons in which the NPY and AgRP are as a melanocortin receptor blocker. Both cause to weight gain (65) and decrease energy expenditure (80, 81). In contrast to POMC neuron, the effect of LEP on NPY/AgRP neurons is inhibitory (36). Several circulating factors, including LEP and insulin, had been suggested to suppress the acute activity of NPY/AgRP neurons. The inhibitory effects of LEP and insulin in NPY/AgRP neurons have been directly associated with that of PI3K (82-87). Evidence also suggests a stimulatory effect of central NPY on insulin release. Venticular delivery of NPY promotes insulin secretion and potentiates the insulinnemic response to hyperglycemia, independently of food intake (88). Hypothalamic NPY secretion can be regulated by insulin hormone, and also the high level of insulin can inhibit the synthesis and release of NPY (71).

In the present study, the expression of LEPR gene in the treatment groups showed that this increase in Ins. and MSC therapy groups was higher than other groups. Also, by increasing the level of LEP and subsequently the LEPR expression increment, the expression rates of MC4R increased and NPY decreased in the treatment groups, which was consistent with previous studies (89, 90). These changes were more prominent in the groups that received MSCs indicating the positive effect of cell therapy on reducing the expression of NPY and increasing the expression of MC4R, which follows an increase in appetite stimulation and gaining weight.

Finally, the weight of mice in treatment groups in general increased at the end of study, but in groups treated with metformin this increase was lower than other groups that showed the side effect of metformin on weight loss. All in all, using WJ-MSCs in combination with insulin may modulate energy balance, and also these cells are favorite for short investigations because of low tumorigenesity and immunogenicity, but the use of them in the long term must be investigated in future studies.

**Conclusion**

Our study showed that infusion of WJ-MSCs and combined therapy of WJ-MSCs with insulin can significantly improve energy expenditure and weight gain in rats by changing the amount of LEP and subsequent changes in the expression of NPY and MC4R. In future studies, it is suggested to follow the effects of these cells with different protocol, i.e. with more frequent intervals and lower doses, as well as synergistic effect of them with insulin on diabetic animal and preclinical study.

**Acknowledgment**

This study was supported by Transplant Research Center and grant of Vice Chancellor of Research, Shiraz University of Medical Sciences, Shiraz, Iran.

**Conflicts of Interest**

The authors declare that there are no conflicts of interest.

**Financial Disclosure**

Shiraz Transplant Research Center and Vice Chancellor of Research, Shiraz University of Medical Sciences, Shiraz, Iran, grant number 95-01-15-12351.

**References**

1. Ezquer F, Ezquer M, Contadora D, Ricca M, Simon V, Conge P. The antidiabetic effect of mesenchymal stem cells is unrelated to their transdifferentiation potential but to their capability to restore Th1/Th2 balance and to modify the pancreatic microenvironment. Stem Cells 2012; 30:1664-1674.
2. Dave SD, Trivedi HL, Gopal SC, Chandra T. Case Report: Combined therapy of insulin-producing cells and haematopoietic stem cells offer better diabetic control than only haematopoietic stem cells’ infusion for patients with insulin-dependent diabetes. BMJ Case Rep 2014; 2014:1-3.
3. Chen L, Gao G-Q, Wang L, Song J, Chen B, Xu YX, et al. Allogeneic diabetic mesenchymal stem cells transplantation in streptozotocin-induced diabetic rat. Clin Invest Med 2008; 31:328-337.
4. Gao X, Song L, Shen K, Wang H, Qian M, Niu W, et al. Bone
Effect of mesenchymal stem cells on diabetes

Sabet Sarvestani et al.

marrow mesenchymal stem cells promote the repair of islets from diabetic mice through paracrine actions. Mol Cell Endocrinol 2014; 388:41-50.

5. Le PT-B, Van Pham P, Vu NB, Dang LT-T, Phan NK. Expanded autologous adipose derived stem cell transplantation for type 2 diabetes mellitus. Biomed Res Ther 2016; 3:1034-1044.

6. Si Y, Zhao Y, Hao H, Liu J, Guo Y, Mu Y, et al. Infusion of mesenchymal stem cells ameliorates hyperglycemia in type 2 diabetic rats: identification of a novel role in improving insulin sensitivity. Diabetes 2012; 61:1616-1625.

7. Dang LT-T, Bui AN-T, Pham VM, Phan NK, Van Pham P. Production of islet-like insulin-producing cell clusters from adipose-derived stem cells. Biomed Res Ther 2015; 2:184-192.

8. Voltarelli JC, Couri CE, Rodrigues MC, Moraes DA, Stracieri A-BF, Pieroni F, et al. Stem cell therapies for type 1 diabetes mellitus. Indian J Exp Biol 2011; 49:395-400.

9. Wu C, Liu F, Li P, Zhao G, Lan S, Jiang W, et al. Engineered hair follicle mesenchymal stem cells overexpressing controlled-release insulin reverse hyperglycemia in mice with type 1 diabetes. Cell Transplant 2015; 24:991-997.

10. Wu XL, Liu C-P, Xu K-E, Mu X-D, Zhu J, Jiang J-J, et al. Reversal of hyperglycemia in diabetic rats by portal vein transplantation of islet-like cells generated from bone marrow mesenchymal stem cells. World J Gastroenterol 2007; 13:3342-3349.

11. Xiao N, Zhao X, Luo P, Guo J, Zhao Q, Lu G, et al. Co-transplantation of mesenchymal stromal cells and cord blood cells in treatment of diabetes. Cytotherapy 2013; 15:1374-1384.

12. Xie Z, Hao H, Tong C, Cheng Y, Liu J, Pang Y, et al. Human umbilical cord-derived mesenchymal stem cells elicit macrophages into an anti-inflammatory phenotype to alleviate insulin resistance in type 2 diabetic rats. Stem Cells 2016; 34:627-639.

13. Yang Z, Li K, Yan X, Dong F, Zhao C. Amelioration of diabetic retinopathy by engrafted human adipose-derived mesenchymal stem cells in streptozotocin diabetic rats. Graefes Arch Clin Exp Ophthalmol 2010; 248:1415-1422.

14. Zhou H, Tian H-m, Long Y, Zhang Xs, Zhong L, Deng L, et al. Mesenchymal stem cells transplantation mildly ameliorates experimental diabetic nephropathy in rats. Chin Med J 2009; 122:2573-2579.

15. Dang LT-T, Phan NK, Truong KD. Mesenchymal stem cells for diabetes mellitus treatment: new advances. Biomed Res Ther 2017; 4:1062-1081.

16. Van Pham P, Vu NB, Pham VM, Truong NH, Pham TL-B, Dang LT-T, et al. Good manufacturing practice-compliant isolation and culture of human umbilical cord blood-derived mesenchymal stem cells. J Transl Med 2014; 12:56-66.

17. Ren H, Sang Y, Zhang F, Liu Z, Qi N, Chen Y. Comparative analysis of human mesenchymal stem cells from umbilical cord, dental pulp, and menstrual blood as sources for cell therapy. Stem Cells Int 2016; 2016:3516574-3516587.

18. Van Pham P, Vu NB, Phan NK. Umbilical cord-derived stem cells (MODULATISTM) show strong immunomodulation capacity compared to adipose tissue-derived or bone marrow-derived mesenchymal stem cells. Biomed Res Ther 2016; 3:687-696.

19. Wang Y, Chen X, Cao W, Shi Y. Plasticity of mesenchymal stem cells in immunomodulation: pathological and therapeutic implications. Nat Immunol 2014; 15:1009-1016.

20. Haller MJ, Viener H-L, Wasserfall C, Brusko T, Atkinson MA, Schatz DA. Autologous umbilical cord blood infusion for type 1 diabetes. Exp Hematol 2008; 36:710-715.

21. Montanucci P, Alunno A, Basta G, Bistoni O, Pescara T, Cateri S, et al. Restoration of T cell subsets of patients with type 1 diabetes mellitus by microencapsulated human umbilical cord Wharton jelly-derived mesenchymal stem cells: an in vitro study. Clin Immunol 2016; 163:34-41.

22. Atoui R, Chiu RC. Concise review: immunomodulatory properties of mesenchymal stem cells in cellular transplantation: update, controversies, and unknowns. Stem Cells Transl Med 2012; 1:200-205.

23. Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, Krause D, et al. Minimal criteria for defining multipotent mesenchymal stromal cells: The International Society for cellular therapy position statement. Cytotherapy 2006; 8:315-317.

24. Oh S-H, Muzzonigro TM, Bae S-H, LaPonte JM, Hatch HM, Petersen BE. Adult bone marrow-derived cells trans-differentiating into insulin-producing cells for the treatment of type 1 diabetes. Lab Invest 2004; 84:607-617.

25. Chen L-B, Jiang X-B, Yang L. Differentiation of rat marrow mesenchymal stem cells into pancreatic islet beta-cells. World J Gastroenterol 2004; 10:3016-3020.

26. Nekoei SM, Azarpira N, Sadeghi L, Kamalifar S. In vitro differentiation of human umbilical cord Wharton’s jelly mesenchymal stem cells to insulin producing clusters. World J Clin Cases 2015; 3:640-649.

27. Ranjbaran H, Khalilian A, Rahmani Z, Amiri MM. Differentiation of Wharton’s jelly derived mesenchymal stem cells into insulin producing cells. Int J Hematol Oncol Stem Cell Res 2018; 12:219-228.

28. Uccelli A, Moretta L, Pistoia V. Immunoregulatory function of mesenchymal stem cells. Eur J Immunol 2006; 36:2566-2573.

29. Siegel G, Schäfer R, Dazzi F. The immunosuppressive properties of mesenchymal stem cells. Transplantation 2009; 87:45-49.

30. Uccelli A, Pistoia V, Moretta L. Mesenchymal stem cells: a new strategy for immunosuppression?. Trends Immunol 2007; 28:219-226.

31. Maldonado M, Huang T, Yang L, Xu L, Ma L. Human umbilical cord Wharton jelly cells promote extra-pancreatic insulin formation and repair of renal damage in STZ-induced diabetic mice. Cell Commun Signal 2017; 15:28.

32. Li L, Lu J, Shen S, Jia X, Zhu D. Wharton’s jelly-derived mesenchymal stem cell therapy to improve β-cell function in patients with type 1 diabetes and ketoacidosis: a single-centre, single-group, open-label, phase 2 trial. Lancet Diabetes Endocrinol 2016; 4:17-18.

33. Nakata M, Yamamoto S, Okada T, Ohno H, Ozawa K, et al. Stem cell therapies for type 1 diabetes mellitus: update, controversies, and unknowns. Stem Cells Transl Med 2012; 1:200-205.

34. Amitani M, Asakawa A, Ami T, Inui A. The role of leptin in the control of insulin-glucose axis. Front Neurosci 2013; 7:51-67.

35. Meek TH, Morton GJ. Leptin, diabetes, and the brain. Indian J Endocrinol Metab 2012; 16:SS34-SS42.

36. Middendorfer B, Klein S. Absence of leptin triggers type 1 diabetes. Nat Med 2014; 20:705-706.

37. Fujikawa T, Chuang J-C, Sakata I, Ramadori G, Coppari R. Leptin therapy improves insulin-deficient type 1 diabetes by CNS-dependent mechanisms in mice. Proc Natl Acad Sci U S A 2010; 107:17391-17396.

38. Patterson E, Marques TM, O’Sullivan O, Fitzgerald P, Fitz Gerald GF, Cotter PD, et al. Streptozotocin-induced type-1 diabetes disease onset in Sprague–Dawley rats is associated with an altered intestinal microbiota composition and...
decreased diversity. Microbiolology 2015; 161:182-193.
40. Furman BL. Streptozotocin-induced diabetic models in mice and rats. Curr Protoc Pharmacol 2015; 70:1-20.
41. Federiuk IF, Casey HM, Quinn MJ, Wood MD, Ward KB. Induction of type-1 diabetes mellitus in laboratory rats by use of alloxan: route of administration, pitfalls, and insulin treatment. Comp Med 2004; 54:252-257.
42. Han X, Tao Y-L, Deng Y-P, Yu J-W, Cai J, Ren G-F et al. Metformin ameliorates insulin in STZ-induced diabetic mice. Peer J 2017; 5:3155-3168.
43. Pirjali T, Azarpira N, Pirjali S, Ayatollahi M, Aghaei MH, Shamsabadi TA. Isolation of mesenchymal stem cells from fetal tissues. J Fasa Univ Med Sci 2013; 3:348-259.
44. Goyal U, Jaiswal C, Ta M. Isolation and establishment of mesenchymal stem cells from Wharton’s jelly of human umbilical cord. Stem Cells 2018; 8:2735-2740.
45. El-Nawasany MA, Khedr EG, Motawee ME, Ali ZA, Kamel HE, Abu-Amara TM. Isolation, culture and identification of undifferentiated Wharton’s jelly mesenchymal stem cells (W-JMSCs) derived from the human umbilical cord. Open Sci J Clin Med 2015; 3:182-187.
46. Salehi MS, Namavar MR, Shirazi MRJ, Rahmanifar F, Motahari B, Abu-Amara TM. Isolation, culture and identification of mesenchymal stem cells from fetal Wharton’s jelly. Int J Clin Exp Biomed 2017; 5:3155-3168.
47. Sosenko JM, Palmer JP, Rafkin LE, Krischer JP, Cuthbertson BE, Greenbaum CJ, et al. Trends of earlier and later responses of beta-cell beta-cells and its circulation in blood. Nature 1969; 224:697-700.
48. Hu J, Wang F, Sun R, Wang Z, Yu X, Wang L, et al. Effect and mechanisms of combined therapy of human Wharton’s jelly-derived mesenchymal stem cells on type 1 diabetes in NOD model. Endocrine 2015; 48:124-134.
49. Hu J, Wang F, Sun R, Wang Z, Yu X, Wang L, et al. Effect of combined therapy of human Wharton’s jelly-derived mesenchymal stem cells from umbilical cord with sitagliptin in type 2 diabetic rats. Endocrine 2014; 45:279-287.
50. Phadnis SM, Ghasalbadi SM, Hardikar AA, Bhonde RR. Mesenchymal stem cells derived from bone marrow of diabetic patients portrait unique markers influenced by the diabetic microenvironment. Rev Diabet Stud 2009; 6:260-270.
51. Xin Y, Jiang X, Wang Y, Su X, Sun M, Zhang L, et al. Insulin producing cells differentiated from human bone marrow mesenchymal stem cells in vitro ameliorate streptozotocin-induced diabetic hyperglycemia. PLoS One 2016; 11:145838-145855.
52. Zhang Y, Shen W, Hua J, Lei A, Lv C, Wang H, et al. Pancreatic islet-like clusters from bone marrow mesenchymal stem cells of human first-trimester abortus can cure streptozotocin-induced mouse diabetes. Rejuvenation Res 2010; 13:695-706.
53. Wang M, Song L, Strange C, Dong X, Wang H. Therapeutic effects of adipose stem cells from diabetic mice for the treatment of type 2 diabetes. Mol Ther 2018; 26:1921-1930.
54. Li Z, Zhang Z, Chen X, Zhou J, Xiao X-M. Evaluation of Wharton’s jelly-derived mesenchymal stem cells using a chronic salpingitis model: an animal experiment. Stem Cell Res Ther 2017; 8:232-245.
55. Cai J, Wu Z, Xu X, Liao L, Chen J, Huang L, et al. Umbilical cord mesenchymal stromal cell transplantation in established type 1 diabetes: a pilot randomized controlled open-label clinical study to assess safety and impact on insulin secretion. Diabetes Care 2016; 39:149-157.
56. Rubenstein AH, Clark JL, Melani F, Steiner DF. Secretion of proinsulin C-peptide by pancreatic β cells and its circulation in blood. Nature 1969; 224:697-700.
57. Horwitz DL, Starr JL, Makowski ML, Blackard WG, Rubenstein AH. Proinsulin, insulin, and C-peptide concentrations in human portal and peripheral blood. J Clin Invest 1975; 55:1278-1283.
58. Ferrannini E. The target of metformin in type 2 diabetes. N Engl J Med 2014; 371:1547-1548.
59. Kaul K, Apostolopoulou M, Roden M. Insulin resistance in type 1 diabetes mellitus. Metabolism 2015; 64:1629-1639.
60. Zhou J, Xu G, Yan J, Li K, Bai Z, Cheng W, et al. Rehmannia glutinosa (Gaertn.) DC. polyaccharide ameliorates hyperglycemia, hyperlipemia and vascular inflammation in streptozotocin-induced diabetic mice. J Ethnopharmacol 2015; 164:229-238.
61. Timper K, Brüning JC. Hypothalamic circuits regulating appetite and energy homeostasis: pathways to obesity. Dis Model Mech 2017; 10:679-689.
62. Routh VH, Hao L, Santiago AM, Sheng Z, Zhou C. Hypothalamic glucose sensing: making ends meet. Front Syst Neurosci 2014; 8:236-349.
63. Berglund ED, Vianna CR, Donato J, Kim MH, Chiang J-C, Lee CE, et al. Direct leptin action in POMC neurons regulates glucose homeostasis and hepatic insulin sensitivity in mice. J Clin Invest 2012; 122:1000-1009.
64. Fernández-Formoso G, Pérez-Sieira S, González-Touceda D, Dieguez C, Tovar S. Leptin, 20 years of searching for glucose homeostasis. Life Sci 2015; 140:4-9.
65. Huo L, Gamber K, Gheeley S, Silva J, Huntoon N, Leng X-H, et al. Leptin-dependent control of glucose balance and locomotor activity by POMC neurons. Cell metab 2009; 9:537-547.
66. Hill JW, Williams KW, Ye C, Luo J, Balthasar N, Coppari R, et al. Acute effects of leptin require P13K signaling in hypothalamic proopiomelanocortin neurons in mice. J Clin Invest 2008; 118:1796-1805.
67. Kubota T, Kubota N, Kadowaki T. Imbalanced insulin actions in obesity and type 2 diabetes: key mouse models of insulin signaling pathway. Cell Metab 2017; 25:797-810.
68. Seufferlein T. Leptin effects on pancreatic β-cell gene expression and function. Diabetes 2004; 53:152-158.
69. Zhang Q-J, Yang C-C, Zhang S-Y, Zhang L-H, Li J. Alteration of NPY in hypothalamic and its correlation with leptin and ghrelin during the development of T2DM in a rat model. Springer Plus 2016; 5:1913-1923.
70. La Cava A, Alaggio R, Matarrese G. Unraveling the multiple roles of leptin in inflammation and autoimmunity. J Mol Med 2004; 82:4-11.
71. Perry RJ, Zhang X-M, Zhang D, Kumashiro N, Camporez J-PG, Cline GW, et al. Leptin reverses diabetes by suppression of the hypothalamic-pituitary-adrenal axis. Nature Med 2014; 20:759-770.
72. Bates SH, Stearns WH, Dunden TA, Schubert M, Tso AW, Wang Y, et al. STAT3 signalling is required for leptin regulation of energy balance but not reproduction. Nature 2003; 421:856-859.
73. Cowley MA, Smart JL, Rubinstein M, Cerdán MG, Diano S, Horvath TL, et al. Leptin activates anorexigenic POMC neurons and reduces locomotor activity through an AMPK dependent signaling pathway in the hypothalamus. PLoS One 2012; 7:e31986.
74. Obici S, Feng Z, Tan J, Liu L, Karkkainen G, Rossetti L. Central melanocortin receptors regulate insulin action. J Clin Invest 2001; 108:1079-1085.
75. Adage T, Scheurink AJ, De Boer SF, De Vries K, Konsman JP, Kuipers F, et al. Hypothalamic, metabolic, and behavioral responses to pharmacological inhibition of CNS melanocortin
signaling in rats. J Neurosci 2001; 21:3639-3645.
78. Fan W, Dinulescu DM, Butler AA, Zhou J, Marks DL, Cone RD. The central melanocortin system can directly regulate serum insulin levels. Endocrinol 2000; 141:3072-3079.
79. Savontaus E, Breen TL, Kim A, Yang LM, Chua Jr SC, Wardlaw SL. Metabolic effects of transgenic melanocyte-stimulating hormone overexpression in lean and obese mice. Endocrinol 2004; 145:3881-3891.
80. Novoselova T, Chan L, Clark A. Pathophysiology of melanocortin receptors and their accessory proteins. Best Pract Res Clin Endocrinol Metab 2018; 32:93-106.
81. Park JY, Chong AY, Cochran EK, Kleiner DE, Haller MJ, Schatz DA, et al. Type 1 diabetes associated with acquired generalized lipodystrophy and insulin resistance: the effect of long-term leptin therapy. J Clin Endocrinol Metab 2008; 93:26-31.
82. Spanswick D, Smith M, Mirshamsi S, Routh V, Ashford M. Insulin activates ATP-sensitive K+ channels in hypothalamic neurons of lean, but not obese rats. Nat Neurosci 2000; 3:757-758.
83. Baver SB, Hope K, Guyot S, Bjørbaek C, Kaczorowski C, O’Connell KM. Leptin modulates the intrinsic excitability of AgRP/NPY neurons in the arcuate nucleus of the hypothalamus. J Neurosci 2014; 34:5486-5496.
84. Al-Qassab H, Smith MA, Irvine EE, Guillermet-Guibert J, Clare M, Choudhury AL, et al. Dominant role of the p110β isoform of PI3K over p110α in energy homeostasis regulation by POMC and AgRP neurons. Cell Metab 2009; 10:343-354.
85. Könner AC, Janoschek R, Plum L, Jordan SD, Rother E, MaX, et al. Insulin action in AgRP-expressing neurons is required for suppression of hepatic glucose production. Cell Metab 2007; 5:438-449.
86. Varela L, Horvath TL. Leptin and insulin pathways in POMC and AgRP neurons that modulate energy balance and glucose homeostasis. EMBO Rep 2012; 13:1079-1086.
87. Mirshamsi S, Laidlaw HA, Ning K, Anderson E, Burgess LA, Gray A, et al. Leptin and insulin stimulation of signalling pathways in arcuate nucleus neurones: PKD dependent actin reorganization and K ATP channel activation. BMC Neurosci 2004; 5:54-72.
88. Marks JL, Waite K. Some acute effects of intracerebroventricular neuropeptide Y on insulin secretion and glucose metabolism in the rat. J Neuroendocrinol 1996; 8:507-513.
89. Chen H, Charlat O, Tartaglia LA, Woolf EA, Weng X, Ellis SJ, et al. Evidence that the diabetes gene encodes the leptin receptor: identification of a mutation in the leptin receptor gene in db/db mice. Cell 1996; 84:491-495.
90. Tavares E, Maldonado R, Minano FJ. Aminoprocalditonin-mediated suppression of feeding involves the hypothalamic melanocortin system. Am J Physiol Endocrinol Metab 2013; 304:1251-1262.